Aditxt, Inc. (ADTX): debt financing — Aditxt settles Aldevron dispute with $1.8M; Adimune ships ADI-100 drug substances

Aditxt, Inc.

Settlement with Aldevron: pays $1M cash and issues $824,371.06 promissory note due May 16, 2025, with 1.5% interest if unpaid.
Adimune subsidiary begins shipment of GMP clinical-grade drug substances for final formulation of ADI-100.
Preclinical data: no toxicity, no antibody formation, no organ persistence; immune system not impaired.
Clinical trials planned in Germany (psoriasis, Type 1 Diabetes) and at Mayo Clinic (Stiff Person Syndrome).
Pre-IND meeting with FDA expected Q2 2025; German regulatory pre-submission meetings completed.

item 1.01 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Aditxt, Inc. incurred loan of $824,371.06 with Aldevron, LLC at 1.5% per annum maturing May 16, 2025.

Instrument: loan
Principal: $824,371.06
Counterparty: Aldevron, LLC
Rate: 1.5% per annum
Maturity: May 16, 2025
Event: incurrence

Exact text from the filing

Pursuant to the Settlement Agreement, the Company will pay $1 million and issue a Promissory Note (the “Note”) in the principal amount of $824,371.06 (the “Principal Amount”). The Principal Amount will not bear interest unless it is not repaid in full by its maturity date on May 16, 2025, in which case interest will accrue at a rate of one and one-half percent (1.5%) per annum.

View on SEC.gov

103 debt financings filed in the last 30 days. Browse all debt financings →

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-021205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.